Selected research
Industry Research
Human VEGF Antibody Industry Research Report 2026
Market perspective
The global Human VEGF Antibody market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human VEGF Antibody is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human VEGF Antibody is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human VEGF Antibody include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Boster and Creative Biomart, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human VEGF Antibody market in terms of revenue (US$ million) and, where applicable, sales volume (Kg), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Kg) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human VEGF Antibody Market by Company
Abcam
Abnova
Absolute Antibody
Agrisera
BioLegend
Bio-Rad
Bon Opus Biosciences
Boster
Creative Biomart
Enzo Life Sciences
ImmunoStar
LifeSpan Biosciences
MilliporeSigma
Novus Biologicals
OriGene
ProMab
R&D Systems
Rockland Immunochemicals
Santa Cruz Biotechnology
Sino Biological
US Biological
Thermo Fisher
Human VEGF Antibody Segment by Type
Rabbit
Mouse
Goat
Others
Human VEGF Antibody Segment by Application
Laboratory
Hospital
Others
Human VEGF Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human VEGF Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human VEGF Antibody manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human VEGF Antibody by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human VEGF Antibody in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Human VEGF Antibody Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Human VEGF Antibody Sales (Kg) of Manufacturers (2021-2026)
Table 7. Global Human VEGF Antibody Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Human VEGF Antibody Revenue of Manufacturers (2021-2026)
Table 9. Global Human VEGF Antibody Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Human VEGF Antibody Average Price (US$/g) of Manufacturers (2021-2026)
Table 11. Global Human VEGF Antibody Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Human VEGF Antibody, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Human VEGF Antibody, Product Type & Application
Table 14. Global Human VEGF Antibody Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Human VEGF Antibody by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Abcam Company Information
Table 19. Abcam Business Overview
Table 20. Abcam Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 21. Abcam Human VEGF Antibody Product Portfolio
Table 22. Abcam Recent Developments
Table 23. Abnova Company Information
Table 24. Abnova Business Overview
Table 25. Abnova Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 26. Abnova Human VEGF Antibody Product Portfolio
Table 27. Abnova Recent Developments
Table 28. Absolute Antibody Company Information
Table 29. Absolute Antibody Business Overview
Table 30. Absolute Antibody Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 31. Absolute Antibody Human VEGF Antibody Product Portfolio
Table 32. Absolute Antibody Recent Developments
Table 33. Agrisera Company Information
Table 34. Agrisera Business Overview
Table 35. Agrisera Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 36. Agrisera Human VEGF Antibody Product Portfolio
Table 37. Agrisera Recent Developments
Table 38. BioLegend Company Information
Table 39. BioLegend Business Overview
Table 40. BioLegend Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 41. BioLegend Human VEGF Antibody Product Portfolio
Table 42. BioLegend Recent Developments
Table 43. Bio-Rad Company Information
Table 44. Bio-Rad Business Overview
Table 45. Bio-Rad Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 46. Bio-Rad Human VEGF Antibody Product Portfolio
Table 47. Bio-Rad Recent Developments
Table 48. Bon Opus Biosciences Company Information
Table 49. Bon Opus Biosciences Business Overview
Table 50. Bon Opus Biosciences Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 51. Bon Opus Biosciences Human VEGF Antibody Product Portfolio
Table 52. Bon Opus Biosciences Recent Developments
Table 53. Boster Company Information
Table 54. Boster Business Overview
Table 55. Boster Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 56. Boster Human VEGF Antibody Product Portfolio
Table 57. Boster Recent Developments
Table 58. Creative Biomart Company Information
Table 59. Creative Biomart Business Overview
Table 60. Creative Biomart Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 61. Creative Biomart Human VEGF Antibody Product Portfolio
Table 62. Creative Biomart Recent Developments
Table 63. Enzo Life Sciences Company Information
Table 64. Enzo Life Sciences Business Overview
Table 65. Enzo Life Sciences Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 66. Enzo Life Sciences Human VEGF Antibody Product Portfolio
Table 67. Enzo Life Sciences Recent Developments
Table 68. ImmunoStar Company Information
Table 69. ImmunoStar Business Overview
Table 70. ImmunoStar Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 71. ImmunoStar Human VEGF Antibody Product Portfolio
Table 72. ImmunoStar Recent Developments
Table 73. LifeSpan Biosciences Company Information
Table 74. LifeSpan Biosciences Business Overview
Table 75. LifeSpan Biosciences Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 76. LifeSpan Biosciences Human VEGF Antibody Product Portfolio
Table 77. LifeSpan Biosciences Recent Developments
Table 78. MilliporeSigma Company Information
Table 79. MilliporeSigma Business Overview
Table 80. MilliporeSigma Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 81. MilliporeSigma Human VEGF Antibody Product Portfolio
Table 82. MilliporeSigma Recent Developments
Table 83. Novus Biologicals Company Information
Table 84. Novus Biologicals Business Overview
Table 85. Novus Biologicals Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 86. Novus Biologicals Human VEGF Antibody Product Portfolio
Table 87. Novus Biologicals Recent Developments
Table 88. OriGene Company Information
Table 89. OriGene Business Overview
Table 90. OriGene Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 91. OriGene Human VEGF Antibody Product Portfolio
Table 92. OriGene Recent Developments
Table 93. ProMab Company Information
Table 94. ProMab Business Overview
Table 95. ProMab Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 96. ProMab Human VEGF Antibody Product Portfolio
Table 97. ProMab Recent Developments
Table 98. R&D Systems Company Information
Table 99. R&D Systems Business Overview
Table 100. R&D Systems Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 101. R&D Systems Human VEGF Antibody Product Portfolio
Table 102. R&D Systems Recent Developments
Table 103. Rockland Immunochemicals Company Information
Table 104. Rockland Immunochemicals Business Overview
Table 105. Rockland Immunochemicals Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 106. Rockland Immunochemicals Human VEGF Antibody Product Portfolio
Table 107. Rockland Immunochemicals Recent Developments
Table 108. Santa Cruz Biotechnology Company Information
Table 109. Santa Cruz Biotechnology Business Overview
Table 110. Santa Cruz Biotechnology Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 111. Santa Cruz Biotechnology Human VEGF Antibody Product Portfolio
Table 112. Santa Cruz Biotechnology Recent Developments
Table 113. Sino Biological Company Information
Table 114. Sino Biological Business Overview
Table 115. Sino Biological Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 116. Sino Biological Human VEGF Antibody Product Portfolio
Table 117. Sino Biological Recent Developments
Table 118. US Biological Company Information
Table 119. US Biological Business Overview
Table 120. US Biological Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 121. US Biological Human VEGF Antibody Product Portfolio
Table 122. US Biological Recent Developments
Table 123. Thermo Fisher Company Information
Table 124. Thermo Fisher Business Overview
Table 125. Thermo Fisher Human VEGF Antibody Sales (Kg), Revenue (US$ Million), Price (US$/g) and Gross Margin (2021-2026)
Table 126. Thermo Fisher Human VEGF Antibody Product Portfolio
Table 127. Thermo Fisher Recent Developments
Table 128. Global Human VEGF Antibody Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 129. Global Human VEGF Antibody Sales by Region (2021-2026) & (Kg)
Table 130. Global Human VEGF Antibody Sales Market Share by Region (2021-2026)
Table 131. Global Human VEGF Antibody Sales by Region (2027-2032) & (Kg)
Table 132. Global Human VEGF Antibody Sales Market Share by Region (2027-2032)
Table 133. Global Human VEGF Antibody Revenue by Region (2021-2026) & (US$ Million)
Table 134. Global Human VEGF Antibody Revenue Market Share by Region (2021-2026)
Table 135. Global Human VEGF Antibody Revenue by Region (2027-2032) & (US$ Million)
Table 136. Global Human VEGF Antibody Revenue Market Share by Region (2027-2032)
Table 137. North America Human VEGF Antibody Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 138. North America Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 139. North America Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 140. North America Human VEGF Antibody Revenue by Country (2021-2026) & (US$ Million)
Table 141. North America Human VEGF Antibody Revenue by Country (2027-2032) & (US$ Million)
Table 142. Europe Human VEGF Antibody Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 143. Europe Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 144. Europe Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 145. Europe Human VEGF Antibody Revenue by Country (2021-2026) & (US$ Million)
Table 146. Europe Human VEGF Antibody Revenue by Country (2027-2032) & (US$ Million)
Table 147. Asia Pacific Human VEGF Antibody Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 148. Asia Pacific Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 149. Asia Pacific Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 150. Asia Pacific Human VEGF Antibody Revenue by Country (2021-2026) & (US$ Million)
Table 151. Asia Pacific Human VEGF Antibody Revenue by Country (2027-2032) & (US$ Million)
Table 152. South America Human VEGF Antibody Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 153. South America Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 154. South America Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 155. South America Human VEGF Antibody Revenue by Country (2021-2026) & (US$ Million)
Table 156. South America Human VEGF Antibody Revenue by Country (2027-2032) & (US$ Million)
Table 157. Middle East and Africa Human VEGF Antibody Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 158. Middle East and Africa Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 159. Middle East and Africa Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 160. Middle East and Africa Human VEGF Antibody Revenue by Country (2021-2026) & (US$ Million)
Table 161. Middle East and Africa Human VEGF Antibody Revenue by Country (2027-2032) & (US$ Million)
Table 162. Global Human VEGF Antibody Sales by Type (2021-2026) & (Kg)
Table 163. Global Human VEGF Antibody Sales by Type (2027-2032) & (Kg)
Table 164. Global Human VEGF Antibody Sales Market Share by Type (2021-2026)
Table 165. Global Human VEGF Antibody Sales Market Share by Type (2027-2032)
Table 166. Global Human VEGF Antibody Revenue by Type (2021-2026) & (US$ Million)
Table 167. Global Human VEGF Antibody Revenue by Type (2027-2032) & (US$ Million)
Table 168. Global Human VEGF Antibody Revenue Market Share by Type (2021-2026)
Table 169. Global Human VEGF Antibody Revenue Market Share by Type (2027-2032)
Table 170. Global Human VEGF Antibody Price by Type (2021-2026) & (US$/g)
Table 171. Global Human VEGF Antibody Price by Type (2027-2032) & (US$/g)
Table 172. Global Human VEGF Antibody Sales by Application (2021-2026) & (Kg)
Table 173. Global Human VEGF Antibody Sales by Application (2027-2032) & (Kg)
Table 174. Global Human VEGF Antibody Sales Market Share by Application (2021-2026)
Table 175. Global Human VEGF Antibody Sales Market Share by Application (2027-2032)
Table 176. Global Human VEGF Antibody Revenue by Application (2021-2026) & (US$ Million)
Table 177. Global Human VEGF Antibody Revenue by Application (2027-2032) & (US$ Million)
Table 178. Global Human VEGF Antibody Revenue Market Share by Application (2021-2026)
Table 179. Global Human VEGF Antibody Revenue Market Share by Application (2027-2032)
Table 180. Global Human VEGF Antibody Price by Application (2021-2026) & (US$/g)
Table 181. Global Human VEGF Antibody Price by Application (2027-2032) & (US$/g)
Table 182. Key Raw Materials
Table 183. Raw Materials Key Suppliers
Table 184. Human VEGF Antibody Distributors List
Table 185. Human VEGF Antibody Customers List
Table 186. Human VEGF Antibody Industry Trends
Table 187. Human VEGF Antibody Industry Drivers
Table 188. Human VEGF Antibody Industry Restraints
Table 189. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Human VEGF Antibody Product Image
Figure 5. Global Human VEGF Antibody Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Human VEGF Antibody Market Size (2021-2032) & (US$ Million)
Figure 7. Global Human VEGF Antibody Sales (2021-2032) & (Kg)
Figure 8. Global Human VEGF Antibody Average Price (US$/g) & (2021-2032)
Figure 9. Rabbit Product Image
Figure 10. Mouse Product Image
Figure 11. Goat Product Image
Figure 12. Others Product Image
Figure 13. Laboratory Product Image
Figure 14. Hospital Product Image
Figure 15. Others Product Image
Figure 16. Global Human VEGF Antibody Revenue Share by Manufacturers in 2025
Figure 17. Global Manufacturers of Human VEGF Antibody, Manufacturing Sites & Headquarters
Figure 18. Global Top 5 and 10 Human VEGF Antibody Players Market Share by Revenue in 2025
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 20. Global Human VEGF Antibody Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 21. Global Human VEGF Antibody Sales by Region in 2025
Figure 22. Global Human VEGF Antibody Revenue by Region in 2025
Figure 23. North America Human VEGF Antibody Market Size by Country in 2025
Figure 24. North America Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 25. North America Human VEGF Antibody Revenue Market Share by Country (2021-2032)
Figure 26. United States Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 27. Canada Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 28. Europe Human VEGF Antibody Market Size by Country in 2025
Figure 29. Europe Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 30. Europe Human VEGF Antibody Revenue Market Share by Country (2021-2032)
Figure 31. Germany Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. France Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. U.K. Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Italy Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 35. Netherlands Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 36. Asia Pacific Human VEGF Antibody Market Size by Country in 2025
Figure 37. Asia Pacific Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 38. Asia Pacific Human VEGF Antibody Revenue Market Share by Country (2021-2032)
Figure 39. China Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. Japan Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. South Korea Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. India Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Australia Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. China Taiwan Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. Southeast Asia Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 46. Southeast Asia Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 47. South America Human VEGF Antibody Market Size by Country in 2025
Figure 48. South America Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 49. South America Human VEGF Antibody Revenue Market Share by Country (2021-2032)
Figure 50. Mexico Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Brazil Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 52. Argentina Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 53. Colombia Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 54. Middle East and Africa Human VEGF Antibody Market Size by Country in 2025
Figure 55. Middle East and Africa Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 56. Middle East and Africa Human VEGF Antibody Revenue Market Share by Country (2021-2032)
Figure 57. Turkey Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 58. Saudi Arabia Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 59. UAE Human VEGF Antibody Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 60. Global Human VEGF Antibody Sales Market Share by Type (2021-2032)
Figure 61. Global Human VEGF Antibody Revenue Market Share by Type (2021-2032)
Figure 62. Global Human VEGF Antibody Price (US$/g) by Type (2021-2032)
Figure 63. Global Human VEGF Antibody Sales Market Share by Application (2021-2032)
Figure 64. Global Human VEGF Antibody Revenue Market Share by Application (2021-2032)
Figure 65. Global Human VEGF Antibody Price (US$/g) by Application (2021-2032)
Figure 66. Human VEGF Antibody Value Chain
Figure 67. Human VEGF Antibody Production Mode & Process
Figure 68. Direct Comparison with Distribution Share
Figure 69. Distributors Profiles
Figure 70. Human VEGF Antibody Industry Opportunities and Challenges
Scope & coverage.
Types
- Rabbit
- Mouse
- Goat
- Others
Applications
- Laboratory
- Hospital
- Others
Companies covered
- Abcam
- Abnova
- Absolute Antibody
- Agrisera
- BioLegend
- Bio-Rad
- Bon Opus Biosciences
- Boster
- Creative Biomart
- Enzo Life Sciences
- ImmunoStar
- LifeSpan Biosciences
- MilliporeSigma
- Novus Biologicals
- OriGene
- ProMab
- R&D Systems
- Rockland Immunochemicals
- Santa Cruz Biotechnology
- Sino Biological
- US Biological
- Thermo Fisher
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human VEGF Antibody Market Size (2021-2032)
- 2.2.2 Global Human VEGF Antibody Sales (2021-2032)
- 2.2.3 Global Human VEGF Antibody Market Average Price (2021-2032)
- 2.3 Human VEGF Antibody by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rabbit
- 2.3.3 Mouse
- 2.3.4 Goat
- 2.3.5 Others
- 2.4 Human VEGF Antibody by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Laboratory
- 2.4.3 Hospital
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human VEGF Antibody Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human VEGF Antibody Sales (Kg) of Manufacturers (2021-2026)
- 3.3 Global Human VEGF Antibody Revenue of Manufacturers (2021-2026)
- 3.4 Global Human VEGF Antibody Average Price by Manufacturers (2021-2026)
- 3.5 Global Human VEGF Antibody Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human VEGF Antibody, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human VEGF Antibody, Product Type & Application
- 3.8 Global Manufacturers of Human VEGF Antibody, Established Date
- 3.9 Global Human VEGF Antibody Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abcam
- 4.1.1 Abcam Company Information
- 4.1.2 Abcam Business Overview
- 4.1.3 Abcam Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abcam Human VEGF Antibody Product Portfolio
- 4.1.5 Abcam Recent Developments
- 4.2 Abnova
- 4.2.1 Abnova Company Information
- 4.2.2 Abnova Business Overview
- 4.2.3 Abnova Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Abnova Human VEGF Antibody Product Portfolio
- 4.2.5 Abnova Recent Developments
- 4.3 Absolute Antibody
- 4.3.1 Absolute Antibody Company Information
- 4.3.2 Absolute Antibody Business Overview
- 4.3.3 Absolute Antibody Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Absolute Antibody Human VEGF Antibody Product Portfolio
- 4.3.5 Absolute Antibody Recent Developments
- 4.4 Agrisera
- 4.4.1 Agrisera Company Information
- 4.4.2 Agrisera Business Overview
- 4.4.3 Agrisera Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Agrisera Human VEGF Antibody Product Portfolio
- 4.4.5 Agrisera Recent Developments
- 4.5 BioLegend
- 4.5.1 BioLegend Company Information
- 4.5.2 BioLegend Business Overview
- 4.5.3 BioLegend Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioLegend Human VEGF Antibody Product Portfolio
- 4.5.5 BioLegend Recent Developments
- 4.6 Bio-Rad
- 4.6.1 Bio-Rad Company Information
- 4.6.2 Bio-Rad Business Overview
- 4.6.3 Bio-Rad Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bio-Rad Human VEGF Antibody Product Portfolio
- 4.6.5 Bio-Rad Recent Developments
- 4.7 Bon Opus Biosciences
- 4.7.1 Bon Opus Biosciences Company Information
- 4.7.2 Bon Opus Biosciences Business Overview
- 4.7.3 Bon Opus Biosciences Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bon Opus Biosciences Human VEGF Antibody Product Portfolio
- 4.7.5 Bon Opus Biosciences Recent Developments
- 4.8 Boster
- 4.8.1 Boster Company Information
- 4.8.2 Boster Business Overview
- 4.8.3 Boster Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Boster Human VEGF Antibody Product Portfolio
- 4.8.5 Boster Recent Developments
- 4.9 Creative Biomart
- 4.9.1 Creative Biomart Company Information
- 4.9.2 Creative Biomart Business Overview
- 4.9.3 Creative Biomart Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Creative Biomart Human VEGF Antibody Product Portfolio
- 4.9.5 Creative Biomart Recent Developments
- 4.10 Enzo Life Sciences
- 4.10.1 Enzo Life Sciences Company Information
- 4.10.2 Enzo Life Sciences Business Overview
- 4.10.3 Enzo Life Sciences Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Enzo Life Sciences Human VEGF Antibody Product Portfolio
- 4.10.5 Enzo Life Sciences Recent Developments
- 4.11 ImmunoStar
- 4.11.1 ImmunoStar Company Information
- 4.11.2 ImmunoStar Business Overview
- 4.11.3 ImmunoStar Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 ImmunoStar Human VEGF Antibody Product Portfolio
- 4.11.5 ImmunoStar Recent Developments
- 4.12 LifeSpan Biosciences
- 4.12.1 LifeSpan Biosciences Company Information
- 4.12.2 LifeSpan Biosciences Business Overview
- 4.12.3 LifeSpan Biosciences Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 LifeSpan Biosciences Human VEGF Antibody Product Portfolio
- 4.12.5 LifeSpan Biosciences Recent Developments
- 4.13 MilliporeSigma
- 4.13.1 MilliporeSigma Company Information
- 4.13.2 MilliporeSigma Business Overview
- 4.13.3 MilliporeSigma Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 MilliporeSigma Human VEGF Antibody Product Portfolio
- 4.13.5 MilliporeSigma Recent Developments
- 4.14 Novus Biologicals
- 4.14.1 Novus Biologicals Company Information
- 4.14.2 Novus Biologicals Business Overview
- 4.14.3 Novus Biologicals Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Novus Biologicals Human VEGF Antibody Product Portfolio
- 4.14.5 Novus Biologicals Recent Developments
- 4.15 OriGene
- 4.15.1 OriGene Company Information
- 4.15.2 OriGene Business Overview
- 4.15.3 OriGene Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 OriGene Human VEGF Antibody Product Portfolio
- 4.15.5 OriGene Recent Developments
- 4.16 ProMab
- 4.16.1 ProMab Company Information
- 4.16.2 ProMab Business Overview
- 4.16.3 ProMab Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 ProMab Human VEGF Antibody Product Portfolio
- 4.16.5 ProMab Recent Developments
- 4.17 R&D Systems
- 4.17.1 R&D Systems Company Information
- 4.17.2 R&D Systems Business Overview
- 4.17.3 R&D Systems Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 R&D Systems Human VEGF Antibody Product Portfolio
- 4.17.5 R&D Systems Recent Developments
- 4.18 Rockland Immunochemicals
- 4.18.1 Rockland Immunochemicals Company Information
- 4.18.2 Rockland Immunochemicals Business Overview
- 4.18.3 Rockland Immunochemicals Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Rockland Immunochemicals Human VEGF Antibody Product Portfolio
- 4.18.5 Rockland Immunochemicals Recent Developments
- 4.19 Santa Cruz Biotechnology
- 4.19.1 Santa Cruz Biotechnology Company Information
- 4.19.2 Santa Cruz Biotechnology Business Overview
- 4.19.3 Santa Cruz Biotechnology Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Santa Cruz Biotechnology Human VEGF Antibody Product Portfolio
- 4.19.5 Santa Cruz Biotechnology Recent Developments
- 4.20 Sino Biological
- 4.20.1 Sino Biological Company Information
- 4.20.2 Sino Biological Business Overview
- 4.20.3 Sino Biological Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Sino Biological Human VEGF Antibody Product Portfolio
- 4.20.5 Sino Biological Recent Developments
- 4.21 US Biological
- 4.21.1 US Biological Company Information
- 4.21.2 US Biological Business Overview
- 4.21.3 US Biological Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 US Biological Human VEGF Antibody Product Portfolio
- 4.21.5 US Biological Recent Developments
- 4.22 Thermo Fisher
- 4.22.1 Thermo Fisher Company Information
- 4.22.2 Thermo Fisher Business Overview
- 4.22.3 Thermo Fisher Human VEGF Antibody Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Thermo Fisher Human VEGF Antibody Product Portfolio
- 4.22.5 Thermo Fisher Recent Developments
5 Global Human VEGF Antibody Market Scenario by Region
- 5.1 Global Human VEGF Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human VEGF Antibody Sales by Region: 2021-2032
- 5.2.1 Global Human VEGF Antibody Sales by Region: 2021-2026
- 5.2.2 Global Human VEGF Antibody Sales by Region: 2027-2032
- 5.3 Global Human VEGF Antibody Revenue by Region: 2021-2032
- 5.3.1 Global Human VEGF Antibody Revenue by Region: 2021-2026
- 5.3.2 Global Human VEGF Antibody Revenue by Region: 2027-2032
- 5.4 North America Human VEGF Antibody Market Facts & Figures by Country
- 5.4.1 North America Human VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human VEGF Antibody Sales by Country (2021-2032)
- 5.4.3 North America Human VEGF Antibody Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Human VEGF Antibody Market Facts & Figures by Country
- 5.5.1 Europe Human VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human VEGF Antibody Sales by Country (2021-2032)
- 5.5.3 Europe Human VEGF Antibody Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Human VEGF Antibody Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human VEGF Antibody Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human VEGF Antibody Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human VEGF Antibody Market Facts & Figures by Country
- 5.7.1 South America Human VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human VEGF Antibody Sales by Country (2021-2032)
- 5.7.3 South America Human VEGF Antibody Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Human VEGF Antibody Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human VEGF Antibody Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human VEGF Antibody Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human VEGF Antibody Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Human VEGF Antibody Sales by Type (2021-2032)
- 6.1.1 Global Human VEGF Antibody Sales by Type (2021-2032) & (Kg)
- 6.1.2 Global Human VEGF Antibody Sales Market Share by Type (2021-2032)
- 6.2 Global Human VEGF Antibody Revenue by Type (2021-2032)
- 6.2.1 Global Human VEGF Antibody Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human VEGF Antibody Revenue Market Share by Type (2021-2032)
- 6.3 Global Human VEGF Antibody Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human VEGF Antibody Sales by Application (2021-2032)
- 7.1.1 Global Human VEGF Antibody Sales by Application (2021-2032) & (Kg)
- 7.1.2 Global Human VEGF Antibody Sales Market Share by Application (2021-2032)
- 7.2 Global Human VEGF Antibody Revenue by Application (2021-2032)
- 7.2.1 Global Human VEGF Antibody Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human VEGF Antibody Revenue Market Share by Application (2021-2032)
- 7.3 Global Human VEGF Antibody Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human VEGF Antibody Value Chain Analysis
- 8.1.1 Human VEGF Antibody Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human VEGF Antibody Production Mode & Process
- 8.2 Human VEGF Antibody Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human VEGF Antibody Distributors
- 8.2.3 Human VEGF Antibody Customers
9 Global Human VEGF Antibody Analyzing Market Dynamics
- 9.1 Human VEGF Antibody Industry Trends
- 9.2 Human VEGF Antibody Industry Drivers
- 9.3 Human VEGF Antibody Industry Opportunities and Challenges
- 9.4 Human VEGF Antibody Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$2,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst